IP Library Granted Patent US 11,891,644
Granted Patent B2
US 11,891,644 · App. 16/616,928 · Granted Feb 6, 2024

T cells with reduced surface fucosylation and methods of making and using the same

Inventors: Nicole Okeley (Bothell, WA); Jessica Field (Bothell, WA); Shyra Gardai (Bothell, WA); Ryan Heiser (Lake Stevens, WA)
Assignee: Seagen Inc.
C12P21/005A61K31/70A61K31/7024A61K35/17A61P35/02C12N5/0636C12N2500/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,891,644
App. No.
16/616,928
Granted
Feb 6, 2024
Kind
B2
Abstract

Methods of producing T cells having reduced surface fucosylation and use thereof in adoptive cell therapy, in particular, in cancer treatment are provided.

Claims (15)

1. A method of producing T cells having reduced surface fucosylation, the method comprising:

culturing T cells in the presence of an effective amount of a fucose analog in a cell culture medium; wherein

said fucose analog is selected from the group consisting of formulae (I) and (II):

or a pharmaceutically acceptable salt or solvate form thereof, wherein each of formula (I) or (II) can be the alpha or beta anomer or the corresponding aldose form;

R 2 is halogen; each of R 1 , R 3 , and R 4 is independently —OH or a hydrolyzable ester group; and R 5 is —CH 3 , or

each of R 1 , R 2 , R 3 , and R 4 is independently —OH or a hydrolyzable ester group; and R 5 is —C≡CH;

and

wherein said T cells cultured in the presence of the effective amount of said fucose analog have at least about 80% reduced surface fucosylation relative to T cells cultured in the absence of said fucose analog; and wherein the T cells having reduced surface fucosylation are configured to be used in an adoptive cell therapy.

2. The method of claim 1 , further comprising a step of isolating the T cells having reduced surface fucosylation.

3. The method of claim 1 , wherein the fucose analog is 2-deoxy-2-fluoro-L-fucose.

4. The method of claim 1 , wherein the fucose analog is alkynyl fucose peracetate.

5. The method of claim 1 , wherein said T cells comprise human peripheral T cells.

6. The method of claim 1 , wherein said T cells having reduced surface fucosylation are T cells having at least about 85% reduction of surface fucosylation relative to T cells cultured in the absence of said fucose analog.

7. The method of claim 1 , wherein said T cells having reduced surface fucosylation are T cells having at least about 90% reduction of surface fucosylation relative to T cells cultured in the absence of said fucose analog.

8. The method of claim 1 , wherein said T cells having reduced surface fucosylation are T cells having at least about 95% reduction of surface fucosylation relative to T cells cultured in the absence of said fucose analog.

Assignments (1)
CHANGE OF NAME Recorded Oct 19, 2020
From: SEATTLE GENETICS, INC.
To: SEAGEN INC.
Reel/Frame 054122/0812 →
Continuity (2)
Provisional Application 62516536 · Jun 7, 2017
Related Publication 20200149082A1 · May 14, 2020
Cited By (1)
US 12,642,809